Reverse phase protein lysate microarray

Last updated

A reverse phase protein lysate microarray (RPMA) is a protein microarray designed as a dot-blot platform that allows measurement of protein expression levels in a large number of biological samples simultaneously in a quantitative manner when high-quality antibodies are available. [1]

Contents

Technically, minuscule amounts of (a) cellular lysates, from intact cells or laser capture microdissected cells, (b) body fluids such as serum, CSF, urine, vitreous, saliva, etc., are immobilized on individual spots on a microarray that is then incubated with a single specific antibody to detect expression of the target protein across many samples. [2] A summary video of RPPA is available. [3] One microarray, depending on the design, can accommodate hundreds to thousands of samples that are printed in a series of replicates. Detection is performed using either a primary or a secondary labeled antibody by chemiluminescent, fluorescent or colorimetric assays. The array is then imaged and the obtained data is quantified.

Multiplexing is achieved by probing multiple arrays spotted with the same lysate with different antibodies simultaneously and can be implemented as a quantitative calibrated assay. [4] In addition, since RPMA can utilize whole-cell or undissected or microdissected cell lysates, it can provide direct quantifiable information concerning post translationally modified proteins that are not accessible with other high-throughput techniques. [5] [6] Thus, RPMA provides high-dimensional proteomic data in a high throughput, sensitive and quantitative manner. [5] However, since the signal generated by RPMA could be generated from unspecific primary or secondary antibody binding, as is seen in other techniques such as ELISA, or immunohistochemistry, the signal from a single spot could be due to cross-reactivity. Thus, the antibodies used in RPMA must be carefully validated for specificity and performance against cell lysates by western blot. [1] [7]

RPMA has various uses such as quantitative analysis of protein expression in cancer cells, body fluids or tissues for biomarker profiling, cell signaling analysis and clinical prognosis, diagnosis or therapeutic prediction. [1] This is possible as a RPMA with lysates from different cell lines and or laser capture microdissected tissue biopsies of different disease stages from various organs of one or many patients can be constructed for determination of relative or absolute abundance or differential expression of a protein marker level in a single experiment. It is also used for monitoring protein dynamics in response to various stimuli or doses of drugs at multiple time points. [1] Some other applications that RPMA is used for include exploring and mapping protein signaling pathways, evaluating molecular drug targets and understanding a candidate drug's mechanism of action. [8] It has been also suggested as a potential early screen test in cancer patients to facilitate or guide therapeutic decision making.

Other protein microarrays include forward protein microarrays (PMAs) and antibody microarrays (AMAs). PMAs immobilize individual purified and sometimes denatured recombinant proteins on the microarray that are screened by antibodies and other small compounds. AMAs immobilize antibodies that capture analytes from the sample applied on the microarray. [4] [6] The target protein is detected either by direct labeling or a secondary labeled antibody against a different epitope on the analyte target protein (sandwich approach). Both PMAs and AMAs can be classified as forward phase arrays as they involve immobilization of a bait to capture an analyte. In forward phase arrays, each array is incubated with one test sample such as a cellular lysate or a patient's serum, but multiple analytes in the sample are tested simultaneously. [4] Figure 1 shows a forward (using antibody as a bait in here) and reverse phase protein microarray at the molecular level.

Experimental design and procedure

Depending on the research question or the type and aim of the study, RPMA can be designed by selecting the content of the array, the number of samples, sample placement within micro-plates, array layout, type of microarrayer, correct detection antibody, signal detection method, inclusion of control and quality control of the samples. The actual experiment is then set up in the laboratory and the results obtained are quantified and analyzed. The experimental stages are listed below:

Sample collection

Cells are grown in T-25 flasks at 37 degree and 5% CO2 in appropriate medium. [1] Depending on the design of the study, after cells are confluent they could be treated with drugs, growth factors or they could be irradiated before lysis step. For time course studies, a stimulant is added to a set of flasks concurrently and the flasks are then processed at different time points. [1] For drug dose studies, a set of flasks are treated with different doses of the drug and all the flasks are collected at the same time. [1]

If a RPMA containing cell fraction lysates of a tissue/s is to be made, laser capture microdissection (LCM) or fine needle aspiration methods is used to isolate specific cells from a region of tissue microscopically. [4] [8]

Cell lysis

Pellets from cells collected through any of the above means are lysed with a cell lysis buffer to obtain high protein concentration. [1]

Antibody screening

Aliquots of the lysates are pooled and resolved by two-dimensional single lane SDS-PAGE followed by western blotting on a nitrocellulose membrane. The membrane is cut into four-millimeter strips, and each strip is probed with a different antibody. Strips with single band indicate specific antibodies that are suitable for RPMA use. Antibody performance should be also validated with a smaller sample size under identical condition before actual sample collection for RPMA. [1] [7]

RPMA construction

Cell lysates are collected and are serially diluted six to ten times if using colorimetric techniques, or without dilution when fluorometric detection is used (due to the greater dynamic range of fluorescence than colorimetric detection). Serial dilutions are then plated in replicates into a 384- or a 1536-well microtiter plate. [1] The lysates are then printed onto either nitrocellulose or PVDF membrane coated glass slides by a microarrayer such as Aushon BioSystem 2470 or Flexys robot (Genomic solution). [1] [9] Aushon 2470 with a solid pin system is the ideal choice as it can be used for producing arrays with very viscous lysates and it has humidity environmental control and automated slide supply system. [1] That being said, there are published papers showing that Arrayit Microarray Printing Pins can also be used and produce microarrays with much higher throughput using less lysate. [10] The membrane coated glass slides are commercially available from several different companies such as Schleicher and Schuell Bioscience (now owned by GE Whatman www.whatman.com), [9] Grace BioLabs (www.gracebio.com), Thermo Scientific, and SCHOTT Nexterion (www.schott.com/nexterion). [11]

Immunochemical signal detection

After the slides are printed, non-specific binding sites on the array are blocked using a blocking buffer such as I-Block and the arrays are probed with a primary antibody followed by a secondary antibody. Detection is usually conducted with DakoCytomation catalyzed signal amplification (CSA) system. For signal amplification, slides are incubated with streptavidin-biotin-peroxidase complex followed by biotinyl-tyramide/hydrogen peroxide and streptavidin-peroxidase. Development is completed using hydrogen peroxide and scans of the slides are obtained (1). Tyramide signal amplification works as follows: immobilized horseradish peroxidase (HRP) converts tyramide into reactive intermediate in the presence of hydrogen peroxide. Activated tyramide binds to neighboring proteins close to a site where the activating HRP enzyme is bound. This leads to more tyramide molecule deposition at the site; hence the signal amplification. [12] [13]

Lance Liotta and Emanual Petricoin invented the RPMA technique in 2001 (see history section below), and have developed a multiplexed detection method using near-infrared fluorescent techniques. [14] In this study, they report the use of a dual dye-based approach that can effectively double the number of endpoints observed per array, allowing, for example, both phospho-specific and total protein levels to be measured and analyzed at once.

Data quantification and analysis

Once immunostaining has been performed protein expression must then be quantified. The signal levels can be obtained by using the reflective mode of an ordinary optical flatbed scanner if a colorimetric detection technique is used [1] or by laser scanning, such as with a TECAN LS system, if fluorescent techniques are used. Two programs available online (P-SCAN and ProteinScan) can then be used to convert the scanned image into numerical values. [1] These programs quantify signal intensities at each spot and use a dose interpolation algorithm (DI25) to compute a single normalized protein expression level value for each sample. Normalization is necessary to account for differences in total protein concentration between each sample and so that antibody staining can be directly compared between samples. [15] This can be achieved by performing an experiment in parallel in which total proteins are stained by colloidal gold total protein staining or Sypro Ruby total protein staining. [1] When multiple RPMAs are analyzed, the signal intensity values can be displayed as a heat map, allowing for Bayesian clustering analysis and profiling of signaling pathways. [15] An optimal software tool, custom designed for RPMAs is called Microvigene, by Vigene Tech, Inc.

Strengths

The greatest strength of RPMAs is that they allow for high throughput, multiplexed, ultra-sensitive detection of proteins from extremely small numbers of input material, a feat which cannot be done by conventional western blotting or ELISA. [1] [9] The small spot size on the microarray, ranging in diameter from 85 to 200 micrometres, enables the analysis of thousands of samples with the same antibody in one experiment. [9] RPMAs have increased sensitivity and are capable of detecting proteins in the picogram range. [9] Some researchers have even reported detection of proteins in the attogram range. [9] This is a significant improvement over protein detection by ELISA, which requires microgram amounts of protein (6). The increase in sensitivity of RPMAs is due to the miniature format of the array, which leads to an increase in the signal density (signal intensity/area) [9] coupled with tyramide deposition-enabled enhancement. The high sensitivity of RPMAs allows for the detection of low abundance proteins or biomarkers such as phosphorylated signaling proteins from very small amounts of starting material such as biopsy samples, which are often contaminated with normal tissue. [4] Using laser capture microdissection lysates can be analyzed from as few as 10 cells, [4] with each spot containing less than a hundredth of a cell equivalent of protein.

A great improvement of RPMAs over traditional forward phase protein arrays is a reduction in the number of antibodies needed to detect a protein. Forward phase protein arrays typically use a sandwich method to capture and detect the desired protein. [4] [15] This implies that there must be two epitopes on the protein (one to capture the protein and one to detect the protein) for which specific antibodies are available. [15] Other forward phase protein microarrays directly label the samples, however there is often variability in the labeling efficiency for different protein, and often the labeling destroys the epitope to which the antibody binds. [15] This problem is overcome by RPMAs as sample need not be labeled directly.

Another strength of RPMAs over forward phase protein microarrays and western blotting is the uniformity of results, as all samples on the chip are probed with the same primary and secondary antibody and the same concentration of amplification reagents for the same length of time. [9] This allows for the quantification of differences in protein levels across all samples. Furthermore, printing each sample, on the chip in serial dilution (colorimetric) provides an internal control to ensure analysis is performed only in the linear dynamic range of the assay. [4] Optimally, printing of calibrators and high and low controls directly on the same chip will then provide for unmatched ability to quantitatively measure each protein over time and between experiments. A problem that is encountered with tissue microarrays is antigen retrieval and the inherent subjectivity of immunohistochemistry. Antibodies, especially phospho-specific reagents, often detect linear peptide sequences that may be masked due to the three-dimensional conformation of the protein. [15] This problem is overcome with RPMAs as the samples can be denatured, revealing any concealed epitopes. [15]

Weaknesses

The biggest limitation of RPMA, as is the case for all immunoassays, is its dependence on antibodies for detection of proteins. Currently there is a limited but rapidly growing number of signaling proteins for which antibodies exist that give an analyzable signal. [15] In addition, finding the appropriate antibody could require extensive screening of many antibodies by western blotting prior to beginning RPMA analysis. [1] To overcome this issue, two open resource databases have been created to display western blot results for antibodies that have good binding specificity within the expected range. [1] [16] [17] Furthermore, RPMAs, unlike western blots, do not resolve protein fractions by molecular weight. [1] Thus, it is critical that upfront antibody validation be performed.

History

RPMA was first introduced in 2001 in a paper by Lance Liotta and Emanuel Petricoin who invented the technology. [8] The authors used the technique to successfully analyze the state of pro-survival checkpoint protein at the microscopic transition stage using laser capture microdissection of histologically normal prostate epithelium, prostate intraepithelial neoplasia, and patient-matched invasive prostate cancer. [8] Since then RPMA has been used in many basic biology, translational and clinical research. In addition, the technique has now been brought into clinical trials for the first time whereby patients with metastatic colorectal and breast cancers are chosen for therapy based on the results of the RPMA. This technique has been commercialized for personalized medicine-based applications by Theranostics Health, Inc.

Related Research Articles

Molecular biology is the study of chemical and physical structure of biological macromolecules. It is a branch of biology that seeks to understand the molecular basis of biological activity in and between cells, including biomolecular synthesis, modification, mechanisms, and interactions.

<span class="mw-page-title-main">Northern blot</span> Molecular biology technique

The northern blot, or RNA blot, is a technique used in molecular biology research to study gene expression by detection of RNA in a sample.

<span class="mw-page-title-main">Proteomics</span> Large-scale study of proteins

Proteomics is the large-scale study of proteins. Proteins are vital parts of living organisms, with many functions such as the formation of structural fibers of muscle tissue, enzymatic digestion of food, or synthesis and replication of DNA. In addition, other kinds of proteins include antibodies that protect an organism from infection, and hormones that send important signals throughout the body.

<span class="mw-page-title-main">ELISA</span> Method to detect an antigen using an antibody and enzyme

The enzyme-linked immunosorbent assay (ELISA) is a commonly used analytical biochemistry assay, first described by Eva Engvall and Peter Perlmann in 1971. The assay uses a solid-phase type of enzyme immunoassay (EIA) to detect the presence of a ligand in a liquid sample using antibodies directed against the protein to be measured. ELISA has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries.

<span class="mw-page-title-main">Microarray</span> Small-scale two-dimensional array of samples on a solid support

A microarray is a multiplex lab-on-a-chip. Its purpose is to simultaneously detect the expression of thousands of biological interactions. It is a two-dimensional array on a solid substrate—usually a glass slide or silicon thin-film cell—that assays (tests) large amounts of biological material using high-throughput screening miniaturized, multiplexed and parallel processing and detection methods. The concept and methodology of microarrays was first introduced and illustrated in antibody microarrays by Tse Wen Chang in 1983 in a scientific publication and a series of patents. The "gene chip" industry started to grow significantly after the 1995 Science Magazine article by the Ron Davis and Pat Brown labs at Stanford University. With the establishment of companies, such as Affymetrix, Agilent, Applied Microarrays, Arrayjet, Illumina, and others, the technology of DNA microarrays has become the most sophisticated and the most widely used, while the use of protein, peptide and carbohydrate microarrays is expanding.

<span class="mw-page-title-main">Western blot</span> Analytical technique used in molecular biology

The western blot, or western blotting, is a widely used analytical technique in molecular biology and immunogenetics to detect specific proteins in a sample of tissue homogenate or extract. Besides detecting the proteins, this technique is also utilized to visualize, distinguish, and quantify the different proteins in a complicated protein combination.

<span class="mw-page-title-main">Reverse transcription polymerase chain reaction</span> Laboratory technique to multiply an RNA sample for study

Reverse transcription polymerase chain reaction (RT-PCR) is a laboratory technique combining reverse transcription of RNA into DNA and amplification of specific DNA targets using polymerase chain reaction (PCR). It is primarily used to measure the amount of a specific RNA. This is achieved by monitoring the amplification reaction using fluorescence, a technique called real-time PCR or quantitative PCR (qPCR). Combined RT-PCR and qPCR are routinely used for analysis of gene expression and quantification of viral RNA in research and clinical settings.

<span class="mw-page-title-main">Biochip</span> Substrates performing biochemical reactions

In molecular biology, biochips are engineered substrates that can host large numbers of simultaneous biochemical reactions. One of the goals of biochip technology is to efficiently screen large numbers of biological analytes, with potential applications ranging from disease diagnosis to detection of bioterrorism agents. For example, digital microfluidic biochips are under investigation for applications in biomedical fields. In a digital microfluidic biochip, a group of (adjacent) cells in the microfluidic array can be configured to work as storage, functional operations, as well as for transporting fluid droplets dynamically.

<span class="mw-page-title-main">Immunohistochemistry</span> Common application of immunostaining

Immunohistochemistry (IHC) is the most common application of immunostaining. It involves the process of selectively identifying antigens (proteins) in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. IHC takes its name from the roots "immuno", in reference to antibodies used in the procedure, and "histo", meaning tissue. Albert Coons conceptualized and first implemented the procedure in 1941.

A protein microarray is a high-throughput method used to track the interactions and activities of proteins, and to determine their function, and determining function on a large scale. Its main advantage lies in the fact that large numbers of proteins can be tracked in parallel. The chip consists of a support surface such as a glass slide, nitrocellulose membrane, bead, or microtitre plate, to which an array of capture proteins is bound. Probe molecules, typically labeled with a fluorescent dye, are added to the array. Any reaction between the probe and the immobilised protein emits a fluorescent signal that is read by a laser scanner. Protein microarrays are rapid, automated, economical, and highly sensitive, consuming small quantities of samples and reagents. The concept and methodology of protein microarrays was first introduced and illustrated in antibody microarrays in 1983 in a scientific publication and a series of patents. The high-throughput technology behind the protein microarray was relatively easy to develop since it is based on the technology developed for DNA microarrays, which have become the most widely used microarrays.

Immunoprecipitation (IP) is the technique of precipitating a protein antigen out of solution using an antibody that specifically binds to that particular protein. This process can be used to isolate and concentrate a particular protein from a sample containing many thousands of different proteins. Immunoprecipitation requires that the antibody be coupled to a solid substrate at some point in the procedure.

Biomarker discovery is a medical term describing the process by which biomarkers are discovered. Many commonly used blood tests in medicine are biomarkers. There is interest in biomarker discovery on the part of the pharmaceutical industry; blood-test or other biomarkers could serve as intermediate markers of disease in clinical trials, and as possible drug targets.

<span class="mw-page-title-main">Antibody microarray</span>

An antibody microarray is a specific form of protein microarray. In this technology, a collection of captured antibodies are spotted and fixed on a solid surface such as glass, plastic, membrane, or silicon chip, and the interaction between the antibody and its target antigen is detected. Antibody microarrays are often used for detecting protein expression from various biofluids including serum, plasma and cell or tissue lysates. Antibody arrays may be used for both basic research and medical and diagnostic applications.

A nitrocellulose slide is a glass microscope slide that is coated with nitrocellulose that is used to bind biological material, often protein, for colorimetric and fluorescence detection assays. For this purpose, a nitrocellulose slide is generally considered to be superior to glass, because it binds a great deal more protein, and protects the tertiary structure of the protein. Typically, nitrocellulose slides have a thin, opaque film of nitrocellulose on a standard 25mm × 75 mm glass microscope slide. The film is extremely sensitive to contact, and to foreign material; contact causes deformation and deposition of material, especially liquids.

<span class="mw-page-title-main">Bio-MEMS</span>

Bio-MEMS is an abbreviation for biomedical microelectromechanical systems. Bio-MEMS have considerable overlap, and is sometimes considered synonymous, with lab-on-a-chip (LOC) and micro total analysis systems (μTAS). Bio-MEMS is typically more focused on mechanical parts and microfabrication technologies made suitable for biological applications. On the other hand, lab-on-a-chip is concerned with miniaturization and integration of laboratory processes and experiments into single chips. In this definition, lab-on-a-chip devices do not strictly have biological applications, although most do or are amenable to be adapted for biological purposes. Similarly, micro total analysis systems may not have biological applications in mind, and are usually dedicated to chemical analysis. A broad definition for bio-MEMS can be used to refer to the science and technology of operating at the microscale for biological and biomedical applications, which may or may not include any electronic or mechanical functions. The interdisciplinary nature of bio-MEMS combines material sciences, clinical sciences, medicine, surgery, electrical engineering, mechanical engineering, optical engineering, chemical engineering, and biomedical engineering. Some of its major applications include genomics, proteomics, molecular diagnostics, point-of-care diagnostics, tissue engineering, single cell analysis and implantable microdevices.

<span class="mw-page-title-main">MAGIChip</span>

MAGIChips, also known as "microarrays of gel-immobilized compounds on a chip" or "three-dimensional DNA microarrays", are devices for molecular hybridization produced by immobilizing oligonucleotides, DNA, enzymes, antibodies, and other compounds on a photopolymerized micromatrix of polyacrylamide gel pads of 100x100x20µm or smaller size. This technology is used for analysis of nucleic acid hybridization, specific binding of DNA, and low-molecular weight compounds with proteins, and protein-protein interactions.

The reverse northern blot is a method by which gene expression patterns may be analyzed by comparing isolated RNA molecules from a tester sample to samples in a control cDNA library. It is a variant of the northern blot in which the nucleic acid immobilized on a membrane is a collection of isolated DNA fragments rather than RNA, and the probe is RNA extracted from a tissue and radioactively labelled. A reverse northern blot can be used to profile expression levels of particular sets of RNA sequences in a tissue or to determine presence of a particular RNA sequence in a sample. Although DNA Microarrays and newer next-generation techniques have generally supplanted reverse northern blotting, it is still utilized today and provides a relatively cheap and easy means of defining expression of large sets of genes.

The Strep-tag system is a method which allows the purification and detection of proteins by affinity chromatography. The Strep-tag II is a synthetic peptide consisting of eight amino acids (Trp-Ser-His-Pro-Gln-Phe-Glu-Lys). This peptide sequence exhibits intrinsic affinity towards Strep-Tactin, a specifically engineered streptavidin, and can be N- or C- terminally fused to recombinant proteins. By exploiting the highly specific interaction, Strep-tagged proteins can be isolated in one step from crude cell lysates. Because the Strep-tag elutes under gentle, physiological conditions, it is especially suited for generation of functional proteins.

Suspension array technology is a high throughput, large-scale, and multiplexed screening platform used in molecular biology. SAT has been widely applied to genomic and proteomic research, such as single nucleotide polymorphism (SNP) genotyping, genetic disease screening, gene expression profiling, screening drug discovery and clinical diagnosis. SAT uses microsphere beads to prepare arrays. SAT allows for the simultaneous testing of multiple gene variants through the use of these microsphere beads as each type of microsphere bead has a unique identification based on variations in optical properties, most common is fluorescent colour. As each colour and intensity of colour has a unique wavelength, beads can easily be differentiated based on their wavelength intensity. Microspheres are readily suspendable in solution and exhibit favorable kinetics during an assay. Similar to flat microarrays, an appropriate receptor molecule, such as DNA oligonucleotide probes, antibodies, or other proteins, attach themselves to the differently labeled microspheres. This produces thousands of microsphere array elements. Probe-target hybridization is usually detected by optically labeled targets, which determines the relative abundance of each target in the sample.

<span class="mw-page-title-main">Peptide microarray</span>

A peptide microarray is a collection of peptides displayed on a solid surface, usually a glass or plastic chip. Peptide chips are used by scientists in biology, medicine and pharmacology to study binding properties and functionality and kinetics of protein-protein interactions in general. In basic research, peptide microarrays are often used to profile an enzyme, to map an antibody epitope or to find key residues for protein binding. Practical applications are seromarker discovery, profiling of changing humoral immune responses of individual patients during disease progression, monitoring of therapeutic interventions, patient stratification and development of diagnostic tools and vaccines.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 B. Spurrier, S. Ramalingam, S. Nishizuka (2008). "Reverse-phase protein microarrays for cell signaling analysis". Nature Protocols. Nature publishing Group. 3 (11): 1796–1808. doi:10.1038/nprot.2008.179. PMID   18974738. S2CID   32515881.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ↑ Gagaoua, Mohammed; Bonnet, Muriel; Ellies-Oury, Marie-Pierre; Koning, Leanne De; Picard, Brigitte (2018). "Reverse phase protein arrays for the identification/validation of biomarkers of beef texture and their use for early classification of carcasses". Food Chemistry. 250: 245–252. doi: 10.1016/j.foodchem.2018.01.070 . PMID   29412918. S2CID   46761907.
  3. ↑ O'Mahony, F. C., Nanda, J., Laird, A., Mullen, P., Caldwell, H., Overton, I. M., et al. The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers. J. Vis. Exp. (71), e50221. doi:10.3791/50221 (2013) http://www.jove.com/video/50221/the-use-reverse-phase-protein-arrays-rppa-to-explore-protein.
  4. 1 2 3 4 5 6 7 8 K.M. Sheehan; V.S. Calvert; E.W. Kays; Y. Lu; D. Fishman; V. Espina; J. Aquino; R. Speer; R. Araujo; G.B. Mills; L.A. Liotta; E.F. Petricoin III; J.D. Wulfkuhle (2005). "Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma". Molecular & Cellular Proteomics. The American Society for Biochemistry and Molecular Biology, Inc. 4 (4): 346–355. doi: 10.1074/mcp.T500003-MCP200 . PMID   15671044.
  5. 1 2 B. Spurrier; S. Ramalingam; S. Nishizuka (2008). "Reverse-phase protein lysate microarrays for cell signaling analysis". Nature Protocols. Nature publishing Group. 3 (11): 1796–1808. doi:10.1038/nprot.2008.179. PMID   18974738. S2CID   32515881.
  6. 1 2 C. Hultshig; J. Kreutzberger; H. Seitz; Z. Konthur; K. Bussow; H. Lehrach (2006). "Recent advances of protein microarrays". Current Opinion in Chemical Biology. Elsevier Ltd. 10 (1): 4–10. doi:10.1016/j.cbpa.2005.12.011. hdl: 11858/00-001M-0000-0010-84B0-3 . PMC   7108394 . PMID   16376134.
  7. 1 2 B. Spurrier; F. L. Washburn; S. Asin; S. Ramalingam; S. Nishizuka (2007). "Antibody screening database for protein kinetic modeling". Proteomics. WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 7 (18): 3259–3263. doi:10.1002/pmic.200700117. PMID   17708592. S2CID   1244150.[ dead link ]
  8. 1 2 3 4 C. P. Paweletz; L. Charboneau; V. E. Bichsel; N. L. Simone; T. Chen; J. W. Gillespie; M.R. Emmert-Buck; M. J. Roth; E. F. Petricoin III; L. A. Liotta (2001). "Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invavasion front". Oncogene. Nature publishing group. 20 (16): 1981–9. doi: 10.1038/sj.onc.1204265 . PMID   11360182.
  9. 1 2 3 4 5 6 7 8 A. Ramaswamy; E. Lin; I. Chen; R. Mitra; J. Morrisett; K. Coombes; Z. Ju; M. Kapoor (2005). "Application of protein lysate microarrays to molecular marker verification and quantification" (PDF). Proteome Science. Ramaswamy et al.; licensee BioMed Central Ltd. 9 (3).
  10. ↑ Proteome Science | Full text | Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker
  11. ↑ Grunwald I; Groth E; Wirth I; Schumacher J; Maiwald M; Zoellmer V; Busse M Kapoor (2010). "Surface biofunctionalization and production of miniaturized sensor structures using aerosol printing technologies". Biofabrication. 2 (1): 014106. Bibcode:2010BioFa...2a4106G. doi:10.1088/1758-5082/2/1/014106. PMID   20811121. S2CID   206108783.
  12. ↑ "Questions and Answers About Tyramide Signal Amplification (TSA) - USA". Archived from the original on 2009-03-04. Retrieved 2009-02-27.
  13. ↑ For a detailed protocol of the technique, refer to Spurrier , Ramalingam S., Nishizuka S. (2008). "Reverse-phase protein lysate microarrays for cell signaling analysis". Nature Protocols. 3 (11): 1796–1808. doi:10.1038/nprot.2008.179. PMID   18974738. S2CID   32515881.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ↑ Calvert, V. Tang, Y. Boveia, V. Wulfkuhle, J. Schutz-Geschwender, A Olive, D. Liotta, L. and Petricoin, E. (2004). Development of multiplexed protein profiling and detection using near infrared detection of reverse-phase protein microarrays. Clinical Proteomics Journal. (1):81–89 Archived July 13, 2011, at the Wayback Machine
  15. 1 2 3 4 5 6 7 8 L A. Liotta; V. Espina; A I. Mehta; V. Calvert; K. Rosenblatt; D. Geho; P J. Munson; L. Young; J. Wulfkuhle; E F. Petricoin (2003). "Protein microarrays: Meeting analytical challenges for clinical applications". Cancer Cell. CELL PRESS. 3 (4): 317–325. doi: 10.1016/S1535-6108(03)00086-2 . PMID   12726858.
  16. ↑ AbMiner
  17. ↑ "Archived copy". Archived from the original on 2016-03-03. Retrieved 2019-05-06.{{cite web}}: CS1 maint: archived copy as title (link)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.